Joint Corp Cuts 2026 Sales Guidance as System-Wide Sales Fall 3.1%
JYNT is trading near its 52-week low of $6.79 (8.5% above the low).
Summary
The Joint cut its 2026 system-wide sales outlook to $508M-$512M from $519M-$552M and now expects comp sales of (3.5)% to (2.5)% versus a prior (3)% to 3% range, citing weak consumer spending. Q3 revenue rose 1% to $13.6M, but system-wide sales fell 3.1% to $123.3M and comps were (1.9)%. Continuing-operations net income jumped to $1.5M from $290K and Adjusted EBITDA from continuing operations rose to $2.3M from $1.4M, helped by RD territory buybacks and refranchising; consolidated results swung to a $117K net loss on discontinued-operations charges, and free cash flow was $(509K) versus $1.5M a year ago. Management kept consolidated Adjusted EBITDA guidance at $12.5M-$13.5M and said year-end clinic count will be about 50 lower than 2025 as underperforming clinics close. The board added $5.0M to the buyback after the company spent $3.8M repurchasing 461,000 shares at an average of $8.30 in Q3, exhausting the prior $12M authorization. The guidance cut on sales and comps is the headline risk; the profit and buyback support is the offset.
At the time of this announcement, JYNT was trading at $7.37 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $104.2M. The 52-week trading range was $6.79 to $10.67. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.